A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use

Change in tumor size estimated using longitudinal tumor growth inhibition (TGI) modeling is an early predictive biomarker of clinical outcomes for multiple cancer types. We present the application of TGI modeling for subjects with multiple myeloma (MM). Longitudinal time course changes in M‐protein...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:CPT Pharmacometrics Syst Pharmacol
Glavni autori: Jonsson, F, Ou, Y, Claret, L, Siegel, D, Jagannath, S, Vij, R, Badros, A, Aggarwal, S, Bruno, R
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2015
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4759707/
https://ncbi.nlm.nih.gov/pubmed/26904385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12044
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items